Oura is buying Counsel Health, an AI-native primary care startup, for $625 million. TechCrunch AI reports that the deal was announced Tuesday, just weeks after the smart ring maker put its IPO of up to $2.2 billion on hold indefinitely, citing “uncertainty in the IPO market.” Instead of going public now, Oura is spending its cash to turn a wellness tracker into a healthcare provider.
⚡ The Quick Read
- The deal: Oura is acquiring Counsel Health for $625 million. It’s expected to close before the end of 2027, according to TechCrunch AI.
- The people: Counsel CEO Muthu Alagappan becomes Oura’s chief clinical AI officer. Counsel’s 70 employees are joining too, per Bloomberg.
- The product: Counsel pairs a medical AI chat with licensed physicians. It’s been live inside the Oura app since June.
- The plan: The two companies want to move into preventive care, acute care, and specialty and chronic care.
- The money: Counsel raised a $25 million Series A led by a16z and GV. PitchBook puts its total funding at about $36 million. That’s a big return on a small amount of capital.
🩺 What Counsel Actually Does
Counsel isn’t a symptom checker with a chatbot bolted on. It’s a care model. The AI handles your questions, gives personalized medical advice, and hands you off to a real physician when a clinical decision is needed. Inside the Oura app, that means you can go from “my sleep data looks weird” to talking with a doctor without leaving the app.
Alagappan describes the approach as “keeping physicians in the loop for clinical decisions.” That matters. Medical AI has a trust problem, and regulators are watching closely. A setup where AI handles triage and doctors stay accountable is the most defensible way to sell AI healthcare right now.
Oura CEO Tom Hale summed up the logic: Oura helps members “understand their physiology and, with Counsel, they can take action on their health,” from “quick questions and prescriptions to lab results, chronic care, and referrals.”
📈 Why Oura Is Doing This Now
There are two pressures at work here.
Competition. Oura has led the smart ring market for years, but RingConn and Ultrahuman are coming for it. Hardware gets copied fast. A clinical care layer built on years of biometric data is much harder to copy.
Growth story. Oura’s numbers are strong. Revenue grew 153% year over year to $533 million for the quarter ending September 30. Fiscal 2026 revenue came in around $1.75 billion, up 92%. The company hit an $11 billion valuation after a $900 million round in October 2025. But a ring company and a healthcare company get valued very differently. Owning the care relationship, not just the sensor, gives Oura a stronger story to tell when the IPO window opens again.
🧠 Why This Matters for AI
The interesting part isn’t the ring. It’s the data. Alagappan said Oura gives clinicians “objective context, trended biometrics, and member engagement.” Most telehealth AI starts from zero: a patient types out symptoms and the model guesses. Counsel will now start from months of continuous heart rate, sleep, and temperature data.
That’s a real edge. Medical AI gets much more useful when it has longitudinal context instead of just a snapshot. The company that controls the wearable data has a structural advantage in clinical AI.
Also worth noting: Counsel will keep serving its enterprise partners and plans to expand beyond Oura’s membership. So Oura isn’t just buying a feature. It’s buying a care platform it can sell to others.
🔮 What to Watch
- More wearable-to-care deals. Expect Whoop, Ultrahuman, and others to look for clinical AI partners or acquisition targets. Startups in the space just got a valuation benchmark.
- Regulatory scrutiny. AI handing out prescriptions and medical advice at scale will draw attention from the FDA and state medical boards.
- Subscription upsell. Clinical services are a natural premium tier on top of Oura’s existing membership model.
- Privacy questions. Biometric data flowing into clinical records raises the stakes on how that data gets stored and shared.
The status quo for wearables was simple: track the data, show a score, maybe nudge you to sleep more. Oura is betting the next phase is closing the loop between what your body shows and what a doctor does about it. If it works, the smart ring stops being a gadget and becomes the way you get into the healthcare system.
Full deal details are available in the original TechCrunch AI report.